Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar;76(3):626-628.
doi: 10.1111/all.14595.

Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19

Evangelos Andreakos  1   2 , Maria Papadaki  1 , Charles N Serhan  3
Affiliations
Editorial

Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19

Evangelos Andreakos et al. Allergy. 2021 Mar.
No abstract available

Keywords: COVID-19; SARS-CoV-2; dexamethasone; hyperinflammation; proresolving lipids.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Hypothetical model of dexamethasone mode of action involving inhibition of the cytokine storm and induction of proresolving lipids such as Protectin D1 (PD1) and Resolvin D4. SARS‐CoV‐2 infection triggers hyperinflammation characterized by a “cytokine storm” involving TNF, IL‐1, IL‐6, IL‐8, and MCP‐1 production and release of eicosanoids. Proresolving meditators including protectins, resolvins, and maresins are also induced as an effort of our organism to counterbalance the immune response. These act to reduce inflammation and promote its resolution but may also help resolve coagulation and block viral replication. Strengthening this response through the temporal administration of dexamethasone, triggering conventional anti‐inflammatory effects as well as production of D‐series protectins, could result in notable benefit in patients
See this image and copyright information in PMC

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720. - PMC - PubMed
    1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Int Med. 2020;180(7):934. - PMC - PubMed
    1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID‐19): A Review. JAMA 2020;323(18):1824‐1836. - PubMed
    1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid‐19 ‐ Preliminary Report. N Engl J Med. 2020. 10.1056/NEJMoa2021436. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Weikum ER, Knuesel MT, Ortlund EA, Yamamoto KR. Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol. 2017;18(3):159‐174. - PMC - PubMed

Publication types